• English
  • Français
  • Español
  • Facebook
  • RSS
  • Twitter

Therapeutics Initiative

Independent Healthcare Evidence

  • TI
  • About Us
    • Oversight Committee
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
    • Questions & Answers
  • Therapeutics Letter
  • Our Evidence Reviews
  • Portrait
  • Continuing Education
  • Contact Us
  • Subscribe
Home > PharmacoEpidemiology > Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

May 30, 2014 PharmacoEpidemiology Leave a Comment

Share

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Colin R Dormuth, Kristian B Filion, J Michael Paterson, Matthew T James, Gary F Teare, Colette B Raymond, Elham Rahme, Hala Tamim, Lorraine Lipscombe, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators

BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g3244 (Published 29 May 2014)

Objective: To evaluate the incremental increase in new onset diabetes from higher potency statins compared with lower potency statins when used for secondary prevention.

Design: Eight population based cohort studies and a meta-analysis. Setting Six Canadian provinces and two international databases from the UK and US.

Participants: 136 966 patients aged ≥40 years newly treated with statins between 1 January 1997 and 31 March 2011.

Methods: Within each cohort of patients newly prescribed a statin after hospitalisation for a major cardiovascular event or procedure, we performed as-treated, nested case-control analyses to compare diabetes incidence in users of higher potency statins with incidence in users of lower potency statins. Rate ratios of new diabetes events were estimated using conditional logistic regression on different lengths of exposure to higher potency versus lower potency statins; adjustment for confounding was achieved using high dimensional propensity scores. Meta-analytic methods were used to estimate overall effects across sites.

Main outcome measures: Hospitalisation for new onset diabetes, or a prescription for insulin or an oral antidiabetic drug.

Results: In the first two years of regular statin use, we observed a significant increase in the risk of new onset diabetes with higher potency statins compared with lower potency agents (rate ratio 1.15, 95% confidence interval 1.05 to 1.26). The risk increase seemed to be highest in the first four months of use (rate ratio 1.26, 1.07 to 1.47).

Conclusions: Higher potency statin use is associated with a moderate increase in the risk of new onset diabetes compared with lower potency statins in patients treated for secondary prevention of cardiovascular disease. Clinicians should consider this risk when prescribing higher potency statins in secondary prevention patients.

Read the article at: http://www.bmj.com/content/348/bmj.g3244

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

 

  • About Us
    • Oversight Committee
    • Questions & Answers
    • Steering Committee
    • Working Groups
      • Drug Assessment
      • Education
      • PharmacoEpidemiology
      • Cochrane Hypertension
    • Members
    • TI Surveys
  • Portrait
    • Frequently Asked Questions
    • Portrait Contact
  • Therapeutics Letter
  • Our Evidence Reviews
  • Get Involved
  • Continuing Education
    • Best Evidence
  • Contact Us
  • Terms & Policies
    • Legal Information & Terms of Use
    • Privacy Policy
    • Acceptable Use Policy

Categories

  • News (123)
  • Therapeutics Letter (133)
  • Portrait (1)
  • Drug Assessments (39)
  • PharmacoEpidemiology (75)
  • Podcasts & Videos (50)

Recent Seminars

Dr. Jessica Otte: We Need To Talk About Tramadol

Share

[Feb 10] Therapeutics Initiative Best Evidence Webinar: Sex and Post-SSRI Evidence-based Medicine Dysfunction

Register
Share

[Mar 10] Therapeutics Initiative Virtual Workshop – Using Evidence in Shared Decision Making: A Case-based, Critical Appraisal Approach for Busy Clinicians

Register
Share

Therapeutics Initiative

Our mission is to provide physicians, nurse practitioners, pharmacists, allied health professionals, and the public with up-to-date, independent, evidence-based, practical information on healthcare interventions. Read more Donate

Contact

2176 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3
Contact us
Office: +1 604-822-0700
Fax: +1 604-822-0701

UBC logoISDB logo

Subscribe

Subscribe to receive email notifications from the TI about the Therapeutics Letter, upcoming educational events, personal prescribing portraits and other news and recent publications. SUBSCRIBE

© 1994 - 2021 Therapeutics Initiative · Terms & Policies · TM